Fig. 1.

PS-T inhibits invasion, migration and EMT in breast cancer cells in vitro and in vivo. a The invasiveness of 4 T-1 and MDA-MB-231 cells after treatment with PS-T at 5 μg/mL for 12 h is evaluated using Transwell invasion assays at 24 h (mean  ±  SD, ***P  <  0.001). b Migratory ability of 4 T-1 and MDA-MB-231 cells after treatment with PS-T at different concentrations is evaluated using scratch assays at different time points (mean  ±  SD, **P  <  0.01, ***P  <  0.001). c Mice are treated with normal saline (control), 25 μg/g or 100 μg/g PS-T by oral gavage every other day for 21 days (mean  ±  SD, *P  <  0.05, **P  <  0.01, scale bars: 100 μm). d 4 T-1 and MDA-MB-231 cells are treated with 5 μg/mL PS-T for 24 h. The levels of each EMT marker are quantified using the NIH ImageJ software. (mean  ±  SD, *P  <  0.05 and **P  <  0.01)